In this tutorial, we present an advanced, hands-on tutorial that demonstrates how we use Qrisp to build and execute non-trivial quantum algorithms. We walk through core Qrisp abstractions for quantum ...
In these 2025 Advanced Life Support Guidelines, the American Heart Association provides comprehensive recommendations for the resuscitation and management of adults experiencing cardiac arrest, ...
Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and resistance mutations. The ARROS-1 trial showed a 44% ORR and 48% intracranial ORR, ...
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
Zidesamtinib, a brain-penetrant, TRK-sparing ROS1 TKI, showed activity and manageable safety in pretreated patients with advanced ROS1+ NSCLC. Zidesamtinib achieved a ...
Taletrectinib demonstrates high efficacy in ROS1-positive NSCLC, with an 85% response rate in treatment-naïve patients and 61.7% in pretreated patients. The drug shows impressive progression-free ...
Rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC initiated under FDA's RTOR program, with completion on track for the third quarter of 2025 CAMBRIDGE, Mass., ...
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new and updated results from the pivotal Phase 2 ...
At WCLC, Nuvation Bio will also sponsor a satellite symposium, titled “Under the Microscope: Focusing on ROS1+ NSCLC,” on Sunday, September 7 from 1:45 – 2:45 p.m. CEST. Presenters include Charu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results